Abstract
Despite improvements in cross-sectional imaging and endoscopy, survival rates for patients with high-grade upper tract urothelial carcinoma (UTUC) have not improved in 2 decades. Nearly half of all patients with high-risk features die within 5 years, and patients with locally-advanced disease have less than a 2-year median survival. 1 Lehmann J Suttmann H Kovac I et al. Transitional cell carcinoma of the ureter: prognostic factors influencing progression and survival. Eur Urol. 2007; 51: 1281-1288 Google Scholar , 2 Brown GA Busby JE Wood CG et al. Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: time to change the treatment paradigm?. BJU Int. 2006; 98: 1176-1180 Google Scholar Given the persistently poor prognosis for patients with high-risk UTUC, a shift in treatment paradigm is needed. 3 Liao RS Gupta M Schwen ZR et al. Comparison of pathological stage in patients treated with and without neoadjuvant chemotherapy for high risk upper tract urothelial carcinoma. J Urol. 2018; 200: 68-73 Google Scholar
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
